Mondobiotech Holding Ag Basel (RLFTF)

$0.20 0.02 (9.81%)

14:10 EDT RLFTF Stock Quote Delayed 30 Minutes

What Will the Stock Market Do Today? 3 Big Stories to Watch.

By Sarah Smith, Editor, Today's Market Mar 29, 2021

So what will the stock market do today? It looks like investors will be waiting for updates on infrastructure spending and Archegos Capital.

RLFTF Stock: Why Relief Therapeutics and BRPA Stock Are Soaring Today

RLFTF: Why Little-Known Relief Therapeutics Is Climbing Today

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 4.57M

Day's Range 0.20 - 0.21

52-Week Range 0.02 - 0.95

Dividend & Yield N/A (N/A)

RLFTF Stock Predictions, Articles, and Mondobiotech Holding Ag Basel News

From the Web

Review Of Present Therapies For Covid-19

From Talk Markets May 9, 2021

A summary of authorized drugs for Covid-19, those in development, and those that have failed.

Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR

From Relief Therapeutics Holdings AG May 4, 2021

Acquisition would further diversify Relief's pipeline with both commercial products and clinical-stage programs GENEVA and BALERNA, SWITZERLAND / ACCESSWIRE / May 4, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19-induced lung injury, and APR Applied Pharma Research S.A.

Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome

From Relief Therapeutics Holdings AG Apr 22, 2021

Investigator-sponsored trial being conducted at major medical centers in Switzerland Relief provides update on RLF-100 clinical development in Europe GENEVA, SWITZERLAND, and GUNDELFINGEN, GERMANY / ACCESSWIRE / April 22, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19-induced

Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.

From Relief Therapeutics Holdings AG Apr 19, 2021

GENEVA, SWITZERLAND / ACCESSWIRE / April 19, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), commented today on certain statements made by NeuroRx, Inc., its collaboration partner for the development of RLF-100TM (aviptadil) pursuant to that certain binding collaboration agreement, dated September 18, 2020 (the "Collaboration Agreement"), in Amendment No. 1 to the Form S-4 of

Relief Reports 2020 Financial Results and Provides Business Update

From Relief Therapeutics Holdings AG Apr 15, 2021

GENEVA, SWITZERLAND / ACCESSWIRE / April 15, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19 induced lung injury, today announced its 2020 financial results for the year ended December 31, 2020 and provided a business update. "The past year has

Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant

From Relief Therapeutics Holdings AG Apr 7, 2021

GENEVA, SWITZERLAND / ACCESSWIRE / April 7, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19 induced respiratory disorders, today announced the appointment of J.J. Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant effective